Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ITGB1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ITGB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ITGB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ITGB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ITGB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ITGB1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ITGB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ITGB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ITGB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ITGB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603219 | Prostate | Tumor | viral process | 155/3246 | 415/18723 | 7.20e-23 | 1.12e-19 | 155 |
GO:001905819 | Prostate | Tumor | viral life cycle | 117/3246 | 317/18723 | 4.10e-17 | 1.18e-14 | 117 |
GO:190382919 | Prostate | Tumor | positive regulation of cellular protein localization | 97/3246 | 276/18723 | 6.35e-13 | 6.58e-11 | 97 |
GO:004440319 | Prostate | Tumor | biological process involved in symbiotic interaction | 99/3246 | 290/18723 | 2.71e-12 | 2.37e-10 | 99 |
GO:005212619 | Prostate | Tumor | movement in host environment | 68/3246 | 175/18723 | 1.06e-11 | 8.21e-10 | 68 |
GO:005170119 | Prostate | Tumor | biological process involved in interaction with host | 75/3246 | 203/18723 | 1.69e-11 | 1.22e-09 | 75 |
GO:004206019 | Prostate | Tumor | wound healing | 127/3246 | 422/18723 | 5.32e-11 | 3.41e-09 | 127 |
GO:004440919 | Prostate | Tumor | entry into host | 58/3246 | 151/18723 | 5.78e-10 | 2.99e-08 | 58 |
GO:001604916 | Prostate | Tumor | cell growth | 137/3246 | 482/18723 | 7.01e-10 | 3.51e-08 | 137 |
GO:003158916 | Prostate | Tumor | cell-substrate adhesion | 109/3246 | 363/18723 | 1.41e-09 | 6.71e-08 | 109 |
GO:000716317 | Prostate | Tumor | establishment or maintenance of cell polarity | 74/3246 | 218/18723 | 2.00e-09 | 8.86e-08 | 74 |
GO:004671819 | Prostate | Tumor | viral entry into host cell | 55/3246 | 144/18723 | 2.03e-09 | 8.89e-08 | 55 |
GO:007265917 | Prostate | Tumor | protein localization to plasma membrane | 90/3246 | 284/18723 | 2.07e-09 | 8.99e-08 | 90 |
GO:000726514 | Prostate | Tumor | Ras protein signal transduction | 101/3246 | 337/18723 | 6.29e-09 | 2.44e-07 | 101 |
GO:009013217 | Prostate | Tumor | epithelium migration | 105/3246 | 360/18723 | 1.57e-08 | 5.62e-07 | 105 |
GO:009013017 | Prostate | Tumor | tissue migration | 106/3246 | 365/18723 | 1.73e-08 | 6.10e-07 | 106 |
GO:001063117 | Prostate | Tumor | epithelial cell migration | 104/3246 | 357/18723 | 1.97e-08 | 6.91e-07 | 104 |
GO:000166718 | Prostate | Tumor | ameboidal-type cell migration | 130/3246 | 475/18723 | 2.36e-08 | 8.09e-07 | 130 |
GO:000170115 | Prostate | Tumor | in utero embryonic development | 106/3246 | 367/18723 | 2.37e-08 | 8.09e-07 | 106 |
GO:199077815 | Prostate | Tumor | protein localization to cell periphery | 97/3246 | 333/18723 | 5.88e-08 | 1.75e-06 | 97 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGB1 | SNV | Missense_Mutation | | c.2050N>G | p.Gln684Glu | p.Q684E | P05556 | protein_coding | tolerated(0.27) | benign(0.006) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | | c.445A>C | p.Met149Leu | p.M149L | P05556 | protein_coding | deleterious(0.03) | benign(0.398) | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | SNV | Missense_Mutation | | c.826T>C | p.Phe276Leu | p.F276L | P05556 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-BH-A1F6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | rs758287253 | c.1474N>T | p.Asn492Tyr | p.N492Y | P05556 | protein_coding | deleterious(0) | possibly_damaging(0.494) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.1500_1501insCAGCTCTAATCCTCATAACAGTCCTGTGCCTAGAA | p.Glu501GlnfsTer3 | p.E501Qfs*3 | P05556 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.560_561insCTCTAGATGACCTTCTTTGATTTTAGAGGCCTCTTAGTGG | p.Val188SerfsTer3 | p.V188Sfs*3 | P05556 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.1982N>A | p.Cys661Tyr | p.C661Y | P05556 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
ITGB1 | SNV | Missense_Mutation | | c.337N>G | p.Gln113Glu | p.Q113E | P05556 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ITGB1 | SNV | Missense_Mutation | novel | c.1480G>C | p.Gly494Arg | p.G494R | P05556 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.2216N>C | p.Gly739Ala | p.G739A | P05556 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | FIRATEGRAST | FIRATEGRAST | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | 131I-radretumab | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109621 | ABITUZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL2108061 | VOLOCIXIMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | JSM 6427 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 385612210 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL1201607 | NATALIZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | F200 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | R1295 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | GLPG0187 | GLPG-0187 | |